Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms

Videos

Experts review recent updates in the treatment of HCC and discuss how evidence from clinical trials and real-world settings can be applied to clinical practice to improve patient outcomes.

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

Overview of Hepatocellular Carcinoma (HCC)

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Diagnosing Patients With Hepatocellular Carcinoma

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Treatment Approaches for Patients With Early-Stage HCC

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Optimal Sequencing in Patients With Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Safety Profiles of Available Therapies in Advanced HCC

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

The Future of HCC Treatment

R. Katie Kelley, MD, provides an overview of the first-line systemic treatment options for patients with advanced hepatocellular carcinoma.

First-Line Systemic Treatment Options for Patients With Advanced HCC

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.

Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

Dr R. Katie Kelley explains the design and results of the phase 3 CELESTIAL study investigating single-agent cabozantinib for the treatment of advanced hepatocellular carcinoma.

The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

R. Katie Kelley, MD, comments on the safety and efficacy data from the retrospective analysis of the CELESTIAL study in advanced hepatocellular carcinoma.

Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

Dr R. Katie Kelley highlights other abstracts presented at World GI 2023 and shares what she looks forward to in the future of advanced hepatocellular carcinoma treatment.

First-Line Systemic Treatment Options for Patients With Advanced HCC

EP: 1.Overview of Hepatocellular Carcinoma (HCC)

EP: 2.Diagnosing Patients With Hepatocellular Carcinoma

EP: 3.Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

EP: 4.Treatment Approaches for Patients With Early-Stage HCC

EP: 5.The Role of Adjuvant Therapy in Patients With Early-Stage HCC

EP: 6.Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

EP: 7.Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

EP: 8.Optimal Sequencing in Patients With Advanced HCC

EP: 9.Safety Profiles of Available Therapies in Advanced HCC

EP: 10.The Future of HCC Treatment

EP: 11.First-Line Systemic Treatment Options for Patients With Advanced HCC

EP: 12.Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

EP: 13.Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

EP: 14.The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

EP: 15.Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

EP: 16.Future of Advanced HCC Treatment

Latest Conference Coverage